Connect Biopharma Holdings Limited (CNTB)
| Market Cap | 63.30M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -114.36M |
| Shares Out | 55.04M |
| EPS (ttm) | -2.08 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 389,405 |
| Open | 1.13 |
| Previous Close | 1.22 |
| Day's Range | 1.09 - 1.18 |
| 52-Week Range | 0.62 - 2.08 |
| Beta | -0.51 |
| Analysts | Buy |
| Price Target | 7.00 (+508.7%) |
| Earnings Date | Apr 11, 2023 |
About CNTB
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingos... [Read more]
Analyst Forecast
According to one analyst, the rating for CNTB stock is "Buy" and the 12-month stock price forecast is $7.0.
News
Connect Biopharma Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative Colitis
SAN DIEGO, CA and TAICANG, China, June 01, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical ...
Connect Biopharma Reports Full Year 2022 Financial Results and Provides Business Update
CDE's Pre-NDA Feedback Confirms CBP-201 for Atopic Dermatitis on Track for NDA Submission in China by End of First Quarter 2024
Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms
SAN DIEGO & TAICANG, China & SUZHOU, China--(BUSINESS WIRE)--Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company dev...
Connect Biopharma stock up more than 40% after trial data
Connect Biopharma Holdings Ltd. CNTB, -3.51% stock rose more than 40% in the extended session Friday after the company said that analysis of a trial involving one of its therapies to treat moderate-to...
Connect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body Regions
SAN DIEGO & TAICANG, China & SUZHOU, China--(BUSINESS WIRE)--Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company dev...
Connect Biopharma CBP-201 Atopic Dermatitis Abstracts from Two Trials Accepted for Presentation at the American Academy of Dermatology (AAD) Annual Meeting
SAN DIEGO & TAICANG & SUZHOU, China--(BUSINESS WIRE)--Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing...
Connect Biopharma to Present at SVB Securities Global Biopharma Conference and Participate in BioCom California
SAN DIEGO and TAICANG, SUZHOU, China, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB), a global clinical-stage biopharmaceutical company developing T cell-driven th...
Connect Biopharma Provides Business and Clinical Development Program Update
Cash runway now expected to extend into at least 2025 as a result of revised timeline of global Phase 3 program of CBP-201 in atopic dermatitis (AD); Longer cash runway permits continued evaluation of...
Connect Biopharma to Present at the San Francisco Biotech Showcase in January
SAN DIEGO and TAICANG, SUZHOU, China, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical ...
Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
SAN DIEGO and TAICANG, SUZHOU, China, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical ...
Connect Biopharma To Present at Upcoming Investor and Scientific Conferences
SAN DIEGO and TAICANG, SUZHOU, China, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB), a global clinical-stage biopharmaceutical company developing T cell-driven th...
CORRECTING and REPLACING -- Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China
SAN DIEGO and TAICANG, China, Oct. 04, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Connect Biopharma Holdings Limited (Nasdaq: CNTB), please note that in the ...
Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China
SAN DIEGO and TAICANG, China, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company ...
Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic Dermatitis
Conference call and webcast to take place at 5:30 a.m. PDT/8:30 a.m. EDT, tomorrow, Tuesday, October 4
Connect Biopharma Reports First Half 2022 Financial Results and Provides Business Update
– Company expects to report top-line data from China pivotal trial for lead drug candidate CBP-201 in atopic dermatitis in October 2022 –
Connect Biopharma to Report First Half 2022 Financial Results on September 13
Conference call and webcast to follow at 1:30 p.m. PDT/4:30 p.m. EDT
Connect BioPharma Successfully Completes CBP-174 Phase 1 Single Ascending Dose Study
– CBP-174 in development for pruritus associated with allergic and inflammatory skin diseases, including atopic dermatitis, was observed to be safe and well-tolerated –
Connect Moves Forward CBP-201 Top-Line Results Timeline for Pivotal China Atopic Dermatitis Trial to Second Half 2022
— Connect to Evaluate Efficacy and Safety Data on 255 Patients Already Enrolled —
Connect Biopharma to Participate at the Jefferies Healthcare Conference
SAN DIEGO, CA and TAICANG, SUZHOU, China, June 02, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmac...
Connect Biopharma Presents CBP-201 Target Engagement and Immune Modulation Data at the Society for Investigative Dermatology Annual Conference
SAN DIEGO, CA and TAICANG, China, May 17, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical c...
Connect Biopharma Stock Plunges As Ulcerative Colitis Candidate Flunks In Mid-Stage Study
Connect Biopharma Holdings Limited (NASDAQ: CNTB) announced topline results at 12 weeks from its Phase 2 trial for CBP-307 (CBP-307CN002) for ulcerative colitis. CBP-307 0.2 mg demonstrated a numerica...
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
SAN DIEGO, CA and TAICANG, China, May 03, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical c...
Connect Biopharma Reports Full Year 2021 Financial Results and Provides Business Update
- Global Phase 3 Trial of CBP-201 in Moderate-to-Severe Atopic Dermatitis Expected to Commence in H2 2022 - - Topline P ha se 2 CBP-307 Results in Mo d er a te-to- S evere Ulcerative Colitis Expected ...
Connect Biopharma Appoints Autoimmune and Immunology Expert Chin Lee, MD, MPH as Chief Medical Officer
CMO appointment to propel Connect through clinical milestones across solid pipeline of inflammatory disease therapies in development
Connect Biopharma to Participate at the SVB Leerink 11th Annual Global Healthcare Conference
SAN DIEGO and TAICANG, China, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical comp...